Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

• ClinicalTrials.gov Identifier: NCT02437253
• Recruitment Status: Completed
• First Posted: May 7, 2015
• Results First Posted: September 15, 2017
• Last Update Posted: September 15, 2017
• Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
• Information provided by (Responsible Party): Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Tracking Information

• First Submitted Date: May 5, 2015
• First Posted Date: May 7, 2015
• Results First Submitted Date: May 3, 2017
• Results First Posted Date: September 15, 2017
• Last Update Posted Date: September 15, 2017
• Study Start Date: May 2015
• Actual Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 16, 2017)

Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score [ Time Frame: day 0 to week 16 of treatment with adalimumab versus placebo ]

Children's Health Questionnaire - Parent Form 50 bodily pain (BP) standardized score for participants < 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean increased pain. The difference of change in BP standardized score from day 0 to week 16 during adalimumab treatment minus change in BP standardized score from day 0 to week 16 during placebo treatment is reported.

• Original Primary Outcome Measures (submitted: May 5, 2015): Pain measured by the CHQ-PF50 or SF-36 [ Time Frame: after 16 weeks of treatment with adalimumab versus placebo ]

Current Secondary Outcome Measures (submitted: August 16, 2017)

• Children's Health Questionnaire - Parent Form 50 Physical Function (PF) Standardized Score [ Time Frame: Day 0 to week 16 of treatment with adalimumab versus placebo ]
  Children's Health Questionnaire - Parent Form 50 physical function (PF) standardized score for participants < 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean decreased physical function. The difference of change in PF standardized score from day 0 to week 16 during adalimumab treatment minus change in PF standardized score from day 0 to week 16 during placebo treatment is reported.
• Pain Measured by the Visual Analog Scale (VAS) in the Pediatric Pain Questionnaire (PPQ) [ Time Frame: Day 0 to week 16 of treatment with adalimumab versus placebo ]
  Percent of participants with a >10 mm improvement in either "how you feel now" or "worst pain you had this week" on the VA in the PPQ during adalimumab versus during placebo by either parental or subject report. Range is 0-100 mm; lower number means less pain.
• Range of Motion - Bilateral Shoulder, Elbow, Hip, Knee [ Time Frame: Day 0 to week 16 of treatment with adalimumab versus placebo ]
  Number of joints with a >5 degree more positive change during 16 weeks of adalimumab versus 16 weeks of placebo. A total of eight joints were measured.
• Anti-ERT Antibodies [ Time Frame: Day 0 to week 16 of treatment with adalimumab versus placebo ]
  Anti-laronidase antibodies for subjects with MPS I. Anti-idursulfase antibodies for subjects with MPS II.

Original Secondary Outcome Measures (submitted: May 5, 2015)

• Physical function measured by the CHQ-PF50 or SF-36 [ Time Frame: after 16 weeks of treatment with adalimumab versus placebo ]
• Pain measured by the Pediatric Pain Questionnaire [ Time Frame: after 16 weeks of treatment with adalimumab versus placebo ]
• Range of motion - shoulder, elbow, hip, knee [ Time Frame: after 16 weeks of treatment with adalimumab versus placebo ]
• Anti-ERT antibodies [ Time Frame: after 16 weeks of treatment with adalimumab versus placebo ]
• anti-dsDNA antibodies [ Time Frame: after 16 weeks of treatment with adalimumab ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
• Official Title: Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI
• Brief Summary: The purpose of the study is to collect preliminary data on whether the drug adalimumab (also called Humira) can decrease pain and stiffness, improve quality of life, and is safe in people with mucopolysaccharidosis type I, II, or VI. In this study people will be randomly assigned to one of two groups. One group will be treated with adalimumab the first 16 weeks of the study and then with a saline injection for the last 16 weeks of the study. The other group will start with the saline injection for 16 weeks and then switch to adalimumab for the last 16 weeks. The study subject and the study doctor and study coordinator will not know what group a subject is in until the study is done. Adalimumab is given as an injection, just under the skin, every 2 weeks. Both groups will have blood drawn at a screening visit, and then 7 more times over the 32 week study. There will be safety labs done (liver and immune function tests). Other safety tests include a chest X-ray and screening for tuberculosis exposure - these will be done at the screening visit and later in the study if there is concern for tuberculosis exposure or a persistent cough. The following will also be done at screening, the first, middle, and last study visits: 1) a pregnancy test in all girls 8 and older, 2) questionnaires that ask about pain, how MPS impacts social and physical function, and other quality of life questions, 3) height and weight. Finally, a physical exam, that includes for children and adolescents a check of where they are in puberty, will be done by a study physician at the first, middle, and last visits. There are risks to taking adalimumab that include redness and pain where the injection is given, a decreased ability to fight off infections, and others. The safety tests are designed to identify and decrease the risk associated with adalimumab. The study physicians believe that the potential benefit of adalimumab on pain, quality of life, and other MPS related problems outweigh the potential risks of treatment.
• Detailed Description: This is a randomized, pilot study consisting of a 32-week, crossover, double-blind, placebo-controlled treatment phase of subjects with Mucopolysaccharidosis (MPS) types I, II or VI treated with enzyme replacement therapy (ERT) and/or hematopoietic cell transplantation (HCT). Subjects will be treated with adalimumab (group 1) or placebo (group 2) for 16 weeks (i.e., 8 doses) then cross over to the other group for 16 weeks. Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks. Laboratory evaluations and Children's Health Questionnaire - Parent Form 50 (CHQ-PF50) for subjects <18 years of age or the Medical Outcomes Study Short Form-36 (SF-36) for subjects ≥18 years will be assessed at Week 16 and 32 to evaluate early treatment safety and efficacy. Safety will be assessed with laboratory evaluations at 4, 8, 20, and 24 weeks after treatment initiation, and with study visits at week 16 and 32, Physical function will be measured by the CHQ-PF50/SF-36, joint range of motion (ROM), 6-minute walk test (6MWT), and strength testing (hand-grip dynamometer) at baseline, 16, and 32 weeks. Joint inflammation will be measured by serum markers at baseline, 16, and 32 weeks. Anthropometric measurements will also be performed at Baseline and 16 and 32 weeks.
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Mucopolysaccharidosis Type I
• Mucopolysaccharidosis Type II
• Mucopolysaccharidosis Type VI

Intervention

• Drug: Adalimumab
  Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
  Other Name: Humira
• Other: Placebo
  Saline placebo

Study Arms

• Experimental: Adalimumab first, then Placebo
  Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
  Interventions:

  • Drug: Adalimumab
  • Other: Placebo
• Experimental: Placebo first, then Adalimumab
  Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
  Interventions:

  • Drug: Adalimumab
  • Other: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: August 16, 2017): 2
• Original Estimated Enrollment (submitted: May 5, 2015): 4
• Actual Study Completion Date: July 2016
• Actual Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Diagnosis of MPS I, II or VI;
• Treatment with ERT for ≥1 year or no ERT for ≥1 year;
• Weight ≥15 kg;
• Bodily pain reported by the CHQ-PF50 or SF-36 > 1 SD below the general population mean;
• ≥ 3 joints with limitations in motion; and
• Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.

Exclusion Criteria:

• History of HCT less than 2 years prior to enrollment;
• Immune suppression therapy less than 1 year prior to enrollment;
• Active graft versus host disease;
• Current diagnosis or history of lymphoma or other malignancy;
• Current active infection;
• History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);
• Positive TB skin test, positive chest X-ray, or a recent exposure to TB
• Congestive heart failure defined by an ejection fracture <50% measured by ECHO;
• Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);
• Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);
• Hepatitis B infection (active or chronic carrier);
• Latex sensitivity;
• Pregnancy or breastfeeding;
• Known or suspected allergy to adalimumab or related products;
• Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;
• Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
• Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 5 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02437253
• Other Study ID Numbers: 30535
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
• Original Responsible Party: Same as current
• Current Study Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Lynda E Polgreen, MD, MS; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

• PRS Account: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
• Verification Date: May 2017